Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta- analysis  Prof Ric N Price, MD, Lorenz von Seidlein, PhD, Neena Valecha, MD, Prof Francois Nosten, MD, Prof J Kevin Baird, PhD, Prof Nicholas J White, FRS  The Lancet Infectious Diseases  Volume 14, Issue 10, Pages 982-991 (October 2014) DOI: 10.1016/S1473-3099(14)70855-2 Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 1 Study selection The Lancet Infectious Diseases 2014 14, 982-991DOI: (10.1016/S1473-3099(14)70855-2) Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 2 Forest plot of the risk of recurrence at day 28 in patients treated with chloroquine or chloroquine plus primaquine High dose >6 mg/kg. Low dose 3–5 mg/kg. Very low dose <2 mg/kg. As part of a sensitivity analysis, studies in which no recurrences were recorded before day 28 were assigned a numerator of 1, the derived odds ratio was recalculated as 0·43 (95% CI 0·24–0·79; p=0·006). References for all studies are shown in the appendix. The Lancet Infectious Diseases 2014 14, 982-991DOI: (10.1016/S1473-3099(14)70855-2) Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 3 Location of study sites with documented chloroquine-resistant (A) and chloroquine-sensitive Plasmodium vivax (B) The Lancet Infectious Diseases 2014 14, 982-991DOI: (10.1016/S1473-3099(14)70855-2) Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions

Figure 4 Proportion of patients with parasitaemia on days 2 and 3 The Lancet Infectious Diseases 2014 14, 982-991DOI: (10.1016/S1473-3099(14)70855-2) Copyright © 2014 Price et al. Open Access article distributed under the terms of CC-BY Terms and Conditions